Table 2

Baseline data for bone mineral density (BMD) and serum bone markers in patients with rheumatoid arthritis (RA)

BMD/serum

bone markers

Bisphosphonate group

(n = 42)

Bisphosphonate + statin group

(n = 35)

P-value

Student's t-test


BMD, g/cm2

Radius

0.35 ± 0.08 (0.12, 0.54)

0.33 ± 0.13 (0.11, 0.63)

0.547

Lumbar spine

0.82 ± 0.18 (0.50, 1.32)

0.82 ± 0.180 (0.51, 1.40)

0.974

Femoral neck

0.64 ± 0.09 (0.39, 0.81)

0.60 ± 0.13 (0.33, 0.79)

0.096

NTX, nmol BCE/l

16.3 ± 5.4 (9.7, 35.6)

15.8 ± 4.2 (9.3, 27.9)

0.690

TRACP-5b, μU/dl

357 ± 1287(131, 628)

350 ± 102 (174, 652)

0.820

PICP, ng/ml

612 ± 218 (384, 1490)

562 ± 205 (289, 1340)

0.315

RANKL, pmol/l

0.27 ± 0.36 (0.13, 1.92)

0.16 ± 0.11 (0.13, 0.63)

0.093


Results are presented as mean ± SD (range). NTX, N-terminal telopeptide of type I collagen; TRACP-5b, tartrate-resistant acid phosphate-5b; PICP, C-terminal propeptide of type I procollagen; RANKL, receptor activator of NF-κB ligand. P-values are for comparisons between the two treatment groups.

Nagashima et al. Arthritis Research & Therapy 2012 14:R224   doi:10.1186/ar4063

Open Data